Jacobs Levy Equity Management’s Vyant Bio VYNT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q2
– Sell
-110
Closed -$27K – 1126
2018
Q1
$27K Hold
110
– – ﹤0.01% 987
2017
Q4
$31K Sell
110
-158
-59% -$60.3K ﹤0.01% 972
2017
Q3
$108K Hold
268
– – ﹤0.01% 916
2017
Q2
$159K Hold
268
– – ﹤0.01% 867
2017
Q1
$165K Sell
268
-508
-65% -$181K ﹤0.01% 816
2016
Q4
$157K Buy
+776
New +$176K ﹤0.01% 855

Other funds holding VYNT

Jacobs Levy Equity Management's VYNT Position: Q2 2018 in Review

Jacobs Levy Equity Management sold out of Vyant Bio (VYNT) in Q2 2018, closing a stake of 110 shares — an estimated $27K sold.

Jacobs Levy Equity Management first reported a position in VYNT in Q4 2016 and held it in 6 quarters. The position peaked at $165K in Q1 2017. 23 funds tracked by Wall St. Rank hold VYNT as of Q2 2018.

  • Jacobs Levy Equity Management reported no remaining Vyant Bio position as of Q2 2018 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 110 Vyant Bio shares in Q2 2018, an estimated $27K.
  • Jacobs Levy Equity Management first reported a position in Vyant Bio in Q4 2016 and held it in 6 quarters.
  • Jacobs Levy Equity Management's Vyant Bio position peaked at $165K in Q1 2017.
  • 23 funds tracked by Wall St. Rank held Vyant Bio as of Q2 2018.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2018, filed 14 Aug 2018.